Pacific Biometrics Hires New Associate Director, Business Development
Seattle, Washington, May 21, 2008 - Pacific Biometrics, Inc. (PBI) (OTCBB: PBME) a provider of specialized central laboratory and contract research services, has hired Sheri’ DuMond as its new Associate Director, Business Development. The position reports to the Director of Business Development, Patrick Jackle. Ms. DuMond joins PBI after 9 years at Novartis Pharmaceuticals Corporation, where she was District Manager in the Pacific Northwest region. In her new role, Ms. DuMond will assist Mr. Jackle in promoting PBI’s specialty lab services to pharmaceutical, biotech and diagnostic companies for clinical research nationwide.
Mario Ehlers, MD, PhD, Chief Medical Officer of Pacific Biometrics, commented, “We are absolutely delighted that Sheri’ has joined PBI. Sheri has a stellar record of achievement in sales, consistently exceeding sales targets and winning multiple awards during her 9-year tenure at Novartis. She brings extensive experience and knowledge of the pharmaceutical and healthcare industries, an important requirement for successful marketing of PBI’s laboratory services in support of clinical drug development. Sheri’ is a key new hire who we expect will make a major contribution to our efforts to drive sales and grow revenues going forward. In particular, we will expect Sheri’ to focus on our important East Coast clients in our core areas of expertise, including cardiovascular, metabolic, and bone and joint diseases.”
“Sheri’ DuMond has been a friend and colleague of mine for many years and I’m thrilled that she has agreed to move from a successful career at Novartis to this exciting opportunity at PBI,” said Patrick Jackle, Director of Business Development. “Sheri’ has extensive sales and sales management experience. Most recently, she led a Leadership Team at Novartis which was charged with implementing innovative sales and marketing strategies designed to create novel tactics and to separate the company from its competitors. This is the kind of energy and drive that will make a major contribution at PBI as we strengthen relationships with our existing clients and also open new doors with our exciting new clinical biomarker services.”
Ehlers concluded, “We are very encouraged by our recent successes in signing significant new contracts for specialty testing in the areas of diabetes and arthritis drug development, as well as by the rapid growth of our new, wholly owned subsidiary, Pacific Biomarkers. We believe we have significant momentum as we move into the 2009 fiscal year and Sheri’ is joining us at just the right time to further advance our expanding business development efforts.”
About Pacific Biometrics, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
Pacific Biomarkers, Inc., incorporated February 1, 2008 as a wholly owned subsidiary of Pacific Biometrics, Inc., focuses specifically on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.
For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.Source: Pacific Biometrics, Inc.
Contact:
Pacific Biomarkers, Inc.
Mario Ehlers, President and CEO
(206) 298-0068
Kari Charbonnel, Investors and Media
(206) 298-0068
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including, but not limited to, the growth in revenues and backlog that may result from established and new services, our strategic planning and business development plans, impacts on our financial results, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year ended June 30, 2007 and our Form 10-QSB for the quarters ended September 30, 2007, December 31, 2007, and March 31, 2008).
Home | About PBI | Investors | Lab Services | News/Publications | Test Menu | Contact | Privacy Policy
